Manuscripts and Publications

Filters: Keyword is Severity of Illness Index  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Baugh A, Buhr RG, Quibrera P, Barjaktarevic I, R Barr G, Bowler R, Han MKing, Kaufman JD, Koch AL, Krishnan J et al..  2022.  Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity.. Sleep. 45(8)
Bowler RP, Hansel NN, Jacobson S, R Barr G, Make BJ, Han MK, O'Neal WK, Oelsner EC, Casaburi R, Barjaktarevic I et al..  2017.  Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts.. J Gen Intern Med. 32(12):1315-1322.
F
Fawzy A, Putcha N, Aaron CP, Bowler RP, Comellas AP, Cooper CB, Dransfield MT, Han MK, Hoffman EA, Kanner RE et al..  2019.  Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.. Chest. 155(3):519-527.
G
Garudadri S, Woodruff PG, Han MK, Curtis JL, R Barr G, Bleecker ER, Bowler RP, Comellas A, Cooper CB, Criner G et al..  2019.  Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS.. Chest. 155(5):908-917.
H
Han MK, Quibrera PM, Carretta EE, R Barr G, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL et al..  2017.  Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(8):619-626.
Han MK, Tayob N, Murray S, Woodruff PG, Curtis JL, Kim V, Criner G, Galbán CJ, Ross BD, Hoffman EA et al..  2018.  Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials.. Am J Respir Crit Care Med. 198(2):265-267.
Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, R Barr G et al..  2017.  Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(12):956-967.
K
Keene JD, Jacobson S, Kechris K, Kinney GL, Foreman MG, Doerschuk CM, Make BJ, Curtis JL, Rennard SI, R Barr G et al..  2017.  Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.. Am J Respir Crit Care Med. 195(4):473-481.
M
Martinez CH, Murray S, R Barr G, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2017.  Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Ann Am Thorac Soc. 14(5):636-642.
P
Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciurba FC, Zhang Y, Ortega VE et al..  2021.  Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.. Respir Res. 22(1):127.
S
Smith BM, Hoffman EA, Rabinowitz D, Bleecker E, Christenson S, Couper D, Donohue KM, Han MK, Hansel NN, Kanner RE et al..  2014.  Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS).. Thorax. 69(11):987-96.
Z
Zeidler MR, Martin JL, Kleerup EC, Schneider H, Mitchell MN, Hansel NN, Sundar K, Schotland H, Basner RC, J Wells M et al..  2018.  Sleep disruption as a predictor of quality of life among patients in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS).. Sleep. 41(5)
Zhang WZ, Hoffman KL, Schiffer KT, Oromendia C, Rice MC, Barjaktarevic I, Peters SP, Putcha N, Bowler RP, J Wells M et al..  2021.  Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort.. Respir Res. 22(1):126.
Zhang WZ, Oromendia C, Kikkers SAnn, Butler JJ, O'Beirne S, Kim K, O'Neal WK, Freeman CM, Christenson SA, Peters SP et al..  2020.  Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS.. Sci Rep. 10(1):10562.